Saudi Journal of Gastroenterology

REVIEW ARTICLE
Year
: 2005  |  Volume : 11  |  Issue : 1  |  Page : 1--19

Diagnosis and treatment of viral liver fibrosis


Thierry Poynard, Francoise Imbert-Bismut, Mona Munteanu, Vlad Ratziu 
 Groupe Hospitalier Pitie-Salpetriere, Paris, France

Correspondence Address:
Thierry Poynard
Groupe Hospitalier Pitie-Salpetriere, 47-83 Boulevard de I«SQ»Hospital, 75651 Paris Codex 13
France

This review summarized the diagnostic value of fibrosis biomarkers and the efficacy of anti-viral treatments on fibrosis progression. Non­invasive biomarkers can facilitate the screening and management of chronic hepatitis C and B. Screening for significant fibrosis is-mandatory as very effective anti-viral treatments are available, permitting to stop or to reduce the fibrosis progression. The reduction of fibrosis progression will decrease the mortality due to complications of cirrhosis. In patients with chronic hepatitis C, pegylated interferons combined with ribavirin are effective in reducing fibrosis progression. In patients with chronic hepatitis B, lamivudine, adefovir and pegylated interferon are also effective in reducing fibrosis progression. In patients with chronic hepatitis Delta, pegylated interferon is also effective in reducing fibrosis progression


How to cite this article:
Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. Diagnosis and treatment of viral liver fibrosis.Saudi J Gastroenterol 2005;11:1-19


How to cite this URL:
Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. Diagnosis and treatment of viral liver fibrosis. Saudi J Gastroenterol [serial online] 2005 [cited 2021 Dec 7 ];11:1-19
Available from: https://www.saudijgastro.com/article.asp?issn=1319-3767;year=2005;volume=11;issue=1;spage=1;epage=19;aulast=Poynard;type=0